JP Morgan analyst Arun Jayaram maintains EOG Resources (NYSE:EOG) with a Overweight and lowers the price target from $156 to $148.
Trillium Therapeutics Sponsored Study Titled ‘A Trial of TTI-621 in Combination With Doxorubicin in Patients With Leiomyosarcoma’ Posted To Clinical Trials Website; Study Is Recruiting
https://clinicaltrials.gov/ct2/show/NCT04996004